MA44072A - Anticorps se liant spécifiquement à hla-dr et leurs utilisations - Google Patents

Anticorps se liant spécifiquement à hla-dr et leurs utilisations

Info

Publication number
MA44072A
MA44072A MA044072A MA44072A MA44072A MA 44072 A MA44072 A MA 44072A MA 044072 A MA044072 A MA 044072A MA 44072 A MA44072 A MA 44072A MA 44072 A MA44072 A MA 44072A
Authority
MA
Morocco
Prior art keywords
hla
specifically binding
antibodies specifically
antibodies
binding
Prior art date
Application number
MA044072A
Other languages
English (en)
Inventor
Stephane Becart
Qiang Chen
Karen Duffy
Robin Ernst
Chichi Huang
Robert Kuhn
Xiefan Lin-Schmidt
Jinquan Luo
Christian Martinez
Galina Obmolova
Melissa Swiecki
Sheng-Jiun Wu
Hong Zhou
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA44072A publication Critical patent/MA44072A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044072A 2015-12-17 2016-12-16 Anticorps se liant spécifiquement à hla-dr et leurs utilisations MA44072A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562268570P 2015-12-17 2015-12-17

Publications (1)

Publication Number Publication Date
MA44072A true MA44072A (fr) 2018-10-24

Family

ID=57868343

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044072A MA44072A (fr) 2015-12-17 2016-12-16 Anticorps se liant spécifiquement à hla-dr et leurs utilisations

Country Status (10)

Country Link
US (1) US20180355043A1 (fr)
EP (1) EP3390453A2 (fr)
JP (1) JP2019502698A (fr)
KR (1) KR20180087430A (fr)
CN (1) CN108713027A (fr)
AU (1) AU2016371034A1 (fr)
BR (1) BR112018012344A2 (fr)
CA (1) CA3008819A1 (fr)
MA (1) MA44072A (fr)
WO (1) WO2017106684A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026544A (zh) * 2015-07-17 2018-05-11 医疗法人圣光医疗财团 Nt细胞的贮存方法和存储系统
JP7709376B2 (ja) * 2018-10-23 2025-07-16 ブイオーアール バイオファーマ インコーポレーテッド Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
WO2020089769A1 (fr) * 2018-10-29 2020-05-07 Janssen Biotech, Inc. Anticorps se liant spécifiquement à un complexe hla-dr/colii_259 et leurs utilisations
JP7410143B2 (ja) * 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
WO2020204054A1 (fr) * 2019-04-01 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-hla-dq2.5
US11299545B2 (en) * 2019-04-04 2022-04-12 Janssen Biotech, Inc. Anti-HLA-C antibodies and uses thereof
BR112022001702A2 (pt) * 2019-07-30 2022-06-21 Univ Health Network Moléculas mhc classe ii e métodos de uso das mesmas
CA3137810A1 (fr) * 2019-08-09 2021-02-18 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Production de complexes cmh ii/cii
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
CN113968911B (zh) * 2020-07-24 2023-10-10 江苏晟斯生物制药有限公司 胰岛素-Fc融合蛋白及其应用
CA3186256A1 (fr) * 2020-07-28 2022-02-03 Yoon Aa Choi Anticorps anti-lilrb1 et ses utilisations
WO2022138757A1 (fr) 2020-12-24 2022-06-30 デンカ株式会社 Construction d'adn, vecteur, bactérie et procédé de production de polypeptide
CA3209479A1 (fr) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Agents de liaison et leurs methodes d'utilisation
EP4335868A4 (fr) * 2021-05-07 2025-08-13 Innovent Biologics Suzhou Co Ltd Mutant fc présentant une liaison modifiée au récepteur fc
WO2023076876A1 (fr) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation de réponses immunitaires à des vecteurs viraux
US20250154494A1 (en) * 2021-11-09 2025-05-15 Janssen Biotech, Inc. Microfluidic Co-Encapsulation Device and System and Methods for Identifying T-Cell Receptor Ligands
CN115433281B (zh) * 2022-05-27 2023-09-12 华兰基因工程有限公司 一种抗pd-l1的人源化纳米抗体及其应用
CN117085118A (zh) * 2023-08-22 2023-11-21 北京大学人民医院 一种瓜氨酸化ii型胶原多肽疫苗及其应用
CN118994401B (zh) * 2024-10-22 2025-02-07 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 一种靶向hla-drb5的单域抗体及其应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
KR20050036852A (ko) * 2001-10-15 2005-04-20 기린 비루 가부시키가이샤 항-ｈｌａ-ｄｒ 항체
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
WO2005058251A2 (fr) * 2003-12-15 2005-06-30 Dendreon Corporation Anticorps specifiques de hla-dr, compositions et methodes associees
EP3332808B1 (fr) * 2005-03-03 2020-09-09 Immunomedics Inc. Anticorps humanises l243
EP3050963B1 (fr) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
CA2646965C (fr) 2006-03-24 2016-06-21 Jonathan H. Davis Domaines de proteine heterodimerique d'ingenierie
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CN101970730A (zh) 2007-12-19 2011-02-09 森托科尔奥索生物科技公司 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
CN101525385B (zh) * 2008-03-07 2013-09-11 苏州工业园区晨健抗体组药物开发有限公司 恶性淋巴瘤、自身免疫性疾病抗体药物的筛选及其制备方法和用途
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
EP2424567B1 (fr) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
SI2506871T1 (sl) 2009-11-30 2016-12-30 Janssen Biotech, Inc. Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011143545A1 (fr) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Protéines hétérodimériques et leurs procédés de production et de purification
EP2420253A1 (fr) 2010-08-20 2012-02-22 Leadartis, S.L. Synthèse de molécules polyvalentes et multifonctionnelles avec un domaine de trimérisation de collagène XV
JP6126991B2 (ja) * 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
MX392780B (es) * 2010-10-13 2025-03-24 Janssen Biotech Inc Polinucléotidos que condifican anticuerpos de oncostatina m humana
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
EP2758078A1 (fr) * 2011-09-22 2014-07-30 Immunomedics, Inc. Anticorps anti-hla-dr inhibant les réactions immunitaires allogènes et xénogènes en cas de greffe d'organe
EP2825199A4 (fr) * 2012-03-15 2016-01-27 Janssen Biotech Inc Anticorps dirigés contre l'autotaxine humaine et procédés d'utilisation
KR102216003B1 (ko) 2013-03-15 2021-02-16 얀센 바이오테크 인코포레이티드 재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법
WO2015057906A1 (fr) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Agonistes 1 du récepteur cd200

Also Published As

Publication number Publication date
WO2017106684A2 (fr) 2017-06-22
JP2019502698A (ja) 2019-01-31
WO2017106684A3 (fr) 2017-08-10
EP3390453A2 (fr) 2018-10-24
KR20180087430A (ko) 2018-08-01
CA3008819A1 (fr) 2017-06-22
AU2016371034A1 (en) 2018-05-31
BR112018012344A2 (pt) 2018-12-04
CN108713027A (zh) 2018-10-26
US20180355043A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
MA44072A (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
FR25C1020I1 (fr) Anticorps thérapeutiques et leurs utilisations
EP3370769A4 (fr) Anticorps se liant spécifiquement à tim-3 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
EP3377102C0 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
EP3356416A4 (fr) Anticorps anti-pd-1 et ses utilisations
EP3362482A4 (fr) Anticorps anti-pcsk9 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP2970505A4 (fr) Anticorps bispécifiques et leurs utilisations
EP3349802A4 (fr) Dendrimères lipocationiques et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
EP2953971A4 (fr) Protéines de liaison à il-11r et leurs utilisations